With the discovery that the highly effective anti-CD20 antibody therapies developed to deplete CD20 + B cells deplete CD20 + T cells equally well, a great interest in the biological properties of CD20 + T cells has emerged. In this study we show that CD20 + T cells have a proinflammatory Th1/Tc1 phenotype with a high proliferative capacity to CNS antigens. We also found that the percentage of CD20 + T cells is increased in the blood of patients with multiple sclerosis and are enriched in the CSF of the patients.
Introduction
Multiple sclerosis is a chronic inflammatory disease of the CNS characterized by T cell-mediated demyelination and axonal damage (Compston and Coles, 2008; Sospedra and Martin, 2016) . Within the past decade, it has become clear that B cells also play a role in multiple sclerosis pathogenesis (Sospedra and Martin, 2016) and the development of B cell depleting therapy with rituximab, ofatumumab and ocrelizumab has strengthened this perception (Hauser et al., 2008; Kappos et al., 2011) . The target of these therapies is CD20 expressed on the cellular surface of most B cells. Recently, a subpopulation of T cells expressing CD20 has also been described; and like B cells these T cells are depleted from the blood by the anti-CD20 antibody therapies (Wilk et al., 2009; Palanichamy et al., 2014; Schuh et al., 2016) suggesting that depletion of CD20 + T cells may contribute to the treatment effects. The implication of CD20 + T cells in multiple sclerosis remains to be fully elucidated, and the biological role of the CD20 molecule is unclear. CD20 is proposed to function as part of a complex that forms or controls calcium entry into the cells (Parolini et al., 2012) . Influx of extracellular Ca 2+ in T cells ensures progression of calcium-depending processes such as cell activation, proliferation, apoptosis and NFAT/NFB-induced production of cytokines such as IFN and TNF (Christo et al., 2015) . Accordingly, previous studies have shown increased Ca 2+ influx (Wilk et al., 2009) , increased susceptibility to apoptosis (Wilk et al., 2009) , and increased production of IFN and TNF (Holley et al., 2014; de Bruyn et al., 2015; Schuh et al., 2016) in CD20 + T cells, as compared to CD20 À T cells. This immunological profile of CD20 + T cells suggests that CD20
+ T cells play a central role in tissue inflammation. The purpose of this study was therefore to elucidate a potential role of CD20 + T cells in the pathogenesis of multiple sclerosis and to thoroughly characterize the immunological functions of this cell population.
Materials and methods

Study population and ethics
We included 25 healthy controls (mean 37 years; range 24-56); 25 untreated patients (mean 36 years; range 22-52) and 11 alemtuzumab treated patients (mean 42 years; range 33-58). All patients were diagnosed with relapsing-remitting multiple sclerosis (RRMS) based on the 2010 revised McDonald criteria (McDonald et al., 2001; Polman et al., 2011) . Of the untreated patients, 23 were treatment-naïve; one previously received interferon-b1a and teriflunomide; and one was previously treated with dimethyl fumarate. Both patients terminated their previous treatment more than 3 months before inclusion. Also, the patients were included at least 1 month since last steroid treatment. Patients treated with alemtuzumab had been treated for 2 years at sampling time. The treatment regimen included a first infusion of 60 mg alemtuzumab distributed over 5 days; and a second infusion of 36 mg distributed over 3 days given 12 months after the first. None of the alemtuzumab treated patients exhibited radiological disease activity; and only mild relapses during the period of treatment. Healthy controls included in the study had no autoimmune, neurological, or chronic illness. There was no significant difference in age (P = 0.29) or gender (P = 0.63) distribution between the three groups (Kruskal-Wallis test). In addition, a replication cohort of 12 untreated patients with primary progressive multiple sclerosis (PPMS; mean age 55) and 12 healthy controls (mean age 46 years) was included. All participants gave informed, written consent to participation. The study was approved by the regional scientific ethics committee (protocol number KF-01-314009 and H-16047666). In addition, umbilical cord blood was obtained from six newborns whose mothers consented to participation in the study.
Blood and CSF samples
Ten millilitres of CSF was collected in an ice bath and immediately centrifuged for 10 min at 400g to separate cells from fluid. CSF cells were then instantly stained and analysed by flow cytometry. Venous blood was collected, and peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation with Lymphoprep TM (Axis-Shield) and washed twice in cold PBS/2 mM EDTA. One millilitre of cord blood was collected from each newborn and PBMC separated as for the venous blood.
Flow cytometric analysis of freshly isolated cells
CSF cells and PBMC were incubated in FcR blocking reagent (Miltenyi Biotec) to prevent non-specific antibody binding, and thereafter stained with a combination of fluorochrome-conjugated antibody against: CD3 (AF488, APC, PE-Cy7; UCHT1), CD8 (BV605; RPA-T8), CD20 (PE-Cy7; 2H7), CD28 (PerCPCy5.5; CD28.2), CD45RA (FITC; HI100), CD49d (BV605; 9F10), CD57 (Pacific Blue; HNK-1), CCR2 (BV605; K036C2), CCR5 (AF647; HEK/1/85a), CCR6 (PerCP-Cy5.5; G034E3), CCR7 (PE; G043H7), CXCR3 (AF488, BV421; G025H7), Fas (PerCP-Cy5.5; DX2), MCAM-1 (BV421; P1H12) all from BioLegend, and CD4 (APC-AF750; S3.5), FasL (FITC; SB93a) from Invitrogen. Isotype matched controls were used to correct for non-specific antibody binding and spectral overlap, where appropriate. For Tbet analysis, PBMC were stained with LIVE/DEAD stain (Life Technologies) and antibody against CD3 (BV421; UCHT1; BioLegend), CD4 (APC-AF750; S3.5; Invitrogen), CD8 (APC; RPA-T8; BioLegend) and CD20 (PE-Cy7; 2H7; BioLegend), and thereafter fixated and permeabilized using the True-Nuclear Transcription Factor Buffer Set from BioLegend, according to manufacturer's guidelines. Cells were then intracellularly stained with antibody against Tbet (PerCP-Cy5.5; 4B10; BioLegend) and ROR-t (PE; AFKJS-9; eBiosciences) or corresponding isotype controls. Data were acquired on a FACS Canto II flow cytometer (BD Biosciences) and data analysis performed using FlowJo software (TreeStar, OR, USA).
Fluorescence-activated cell sorting
T cells from freshly drawn blood from healthy controls were negatively isolated using the Human T cell Isolation kit from StemCell Technologies, stained with carboxyfluorescein diacetate succinimidyl ester, CFSE and left to rest for 12 h in culture. Hereafter, CD20
À and CD20 + T cell populations were sorted on a FACS Aria II (BD Biosciences) by fluorescence-activated cell sorting (FACS) using fluorochrome-conjugated antibody against bTCR (BV605; IP26; BioLegend) and CD20 (PE-Cy7; 2H7; BioLegend). The purity of CD20 À T cells was 95% and 90% for CD20 + T cells. Data shown are from four to five independent experiments.
Intracellular cytokine analysis of sorted CD20
À and CD20 + T cells CD20 À and CD20 + T cells (150 000) isolated by FACS were stimulated with 10 ng/ml PMA and 0.5 mg/ml ionomycin for 30 min after which 5 mg/ml brefeldin A was added to the cell culture and the cells further incubated for 4 h at 5% CO 2 , 37 C (all from Sigma-Aldrich); a total stimulation duration of 4:30 h. Cells were then stained with LIVE/DEAD stain (Life Technologies) and fluorochrome-conjugated antibody against CD3 (APC-AF750; 7D6; Invitrogen) and CD4 (BV421; OKT4; Biolegend). CD8 + T cells were defined as CD4 À T cells. Cells were then fixed and permeabilized using Fixation Buffer and Permeabilization Wash Buffer from BioLegend, according to the manufacturer's protocol. Finally, cells were intracellularly stained with fluorochrome-conjugated antibody against IFN (APC; B27), TNF PerCP-Cy5.5; Mab11), GM-CSF (PE; BVD2-21C11), IL-4 (APC; MP4-25D2), IL-13 (PE; JES10-5A2) and LTPE; 359-81-11) or corresponding isotype controls, all from BioLegend. Data were acquired on a FACSCanto II flow cytometer and data analysis performed using FlowJo software.
T cell proliferation assay
CD20
À and CD20 + T cells (100 000) isolated by FACS were cultured in 96-well flat bottom plates coated with 2 mg/ml anti-CD3 antibody (OKT3, BioLegend). The cells were cultured in growth media RPMI 1640/5% human AB serum/pen-strep (RPMI 1640 and pen/strep from Gibco; human AB serum from Invitrogen) with/without 1 mg/ml anti-CD28 antibody (CD28.2; BD Biosciences). After 72 h cells were stained with fluorochrome-conjugated antibody against CD45 (BV510; HI30), CD4 (BV421; OKT4), CD8 (APC; HIT8a) and thereafter with annexin V-PE and propidium iodide in annexin V binding buffer, according to manufacturer's guidelines (BioLegend). Proliferating and non-proliferating cells were defined according to the strength of their CFSE signal.
Cryopreserved CFSE stained PBMC from 18 untreated patients with RRMS and 30 healthy controls were thawed and cultured in growth media with 10 mg/ml myelin oligodendrocyte glycoprotein (MOG; Anaspec Inc), 30 mg/ml myelin basic protein (MBP; HyTest), 5 Â 10 6 cells/ml killed Candida albicans (InvivoGen) as a positive control, or saline as a negative control for 7 days at 5% CO 2 , 37 C. New growth media was added to the cultures after 4 days. After 7 days the cells were stained with fluorochrome-conjugated antibody against CD3 (APC; UCHT1; BioLegend), CD4 (APC-AF750; S3.5; Invitrogen), CD20 (PE-Cy7; 2H7; BioLegend) and proliferation assessed according to the CFSE signal by flow cytometry.
Cell supernatant cytokine analysis
CD20
À and CD20 + T cells (100 000) isolated by FACS were cultured in growth media with/without 1 mg/ml anti-CD28 antibody (CD28.2; BD Biosciences) in 96-well flat bottom plates coated with 2 mg/ml anti-CD3 antibody (OKT3, BioLegend). Culture supernatants were collected after 0, 1, 2, 3, 5 and 7 days and subjected to a multiplex analysis of cytokines according to the manufacturer's instructions (Meso Scale Diagnostics): IL-1, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/IL-23, IL-12p70, IL-13, IL-15, IL-16, IL-17A, CCL-2, CCL-3, CCL-4, CCL-11, CCL-13, CCL-17, CCL-22, CCL-26, GM-CSF, IFN, CXCL-10, LT-, TNF, VEGF.
Statistical analysis
For analysis of age and gender difference between groups the non-parametric Kruskal-Wallis test was applied. For comparison of CD20 À and CD20 + T cell populations from the same individual or of CD20 + T cells from blood and CSF of the same individual the Student's t-test (two-tailed) for paired samples was applied. For comparison of cell populations between healthy controls and patients with RRMS or untreated and alemtuzumab treated patients, the Student's t-test (two-tailed) for unpaired samples was performed. Correlations were assessed by Spearman rank correlation analysis. P 5 0.005 is considered significant, and P 5 0.05 as suggestive of significance.
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results
Increased prevalence of CD20 + T cells in the blood of patients with multiple sclerosis
To investigate a possible implication of CD20 + T cells in the pathogenesis of multiple sclerosis we compared the percentage of CD20 + T cells in blood from healthy controls and patients with RRMS. Earlier studies indicated that both CD4 + and CD8 + T cells can express CD20 (Eggleton et al., 2011; Holley et al., 2014; Palanichamy et al., 2014) , and hence both subtypes were included in our study. Analysis of CD20 + T cells was performed blinded using flow cytometry and a strict gating strategy, excluding doublet cells and CD20 + B cells ( Supplementary  Fig. 1 ). Furthermore, we applied a high standard for statistical significance (P 5 0.005; P 5 0.05 was only considered as suggestive). The analyses showed that the frequency of CD20 + T cells was significantly increased in blood from patients with RRMS; both in the CD4 + (P = 0.0006) and CD8
The CD4:CD8 cell ratio was shifted from the common 2.5 in T cells to 1.4 in the CD20 + T cell population from patients with RRMS ( Fig. 1D) . No difference between the CD4:CD8 cell ratio in RRMS and healthy controls was found (data not shown).
To validate our finding, we included a replication cohort of 12 patients with PPMS and 12 healthy controls. This cohort showed an increased frequency of peripheral CD20 + T cells in patients with PPMS; both in the CD4 (P = 0.0008) and CD8 (P = 0.0052) compartment ( Fig. 1E and F), confirming our observation.
Preferential recruitment of CD20 + T cells to the CSF
Analysing the expression of chemokine receptors and adhesion molecules assumed to navigate blood T cells to the CNS showed that the frequency of blood CD20 + T cells from patients with RRMS expressing CCR2, CCR5, CCR6, CXCR3 and a high level of CD49d (CD49d hi ) was significantly increased compared to CD20 À T cells both in the CD4 + and CD8 + compartment, and MCAM-1 in CD4 + T cells (P 5 0.0001; Fig. 2G -L). The great migration potential of peripheral CD20 + T cells from patients with RRMS was substantiated by the observation that CD20 + T cells were enriched in the CSF of patients (P = 0.0010 for CD4 + ; P 5 0.0001 for CD8 + ; Fig. 3A-C) . In CSF, the frequency of both CD4 + and CD8 + CD20 + T cells expressing CCR2
(P 5 0.0001) and CCR5 (P 5 0.0001), and CD4 + CD20 + T cells expressing MCAM-1 (P = 0.0034) and CCR6 (P = 0.0014) was furthermore significantly increased compared to CD20 À T cells ( Fig. 3D-I ). Comparing the prevalence of CD20 + T cells expressing CCR2, CCR5, CCR6, CXCR6, MCAM-1 or a high level of CD49d between patients with RRMS and healthy controls showed no significant difference between the two groups (Supplementary Fig. 2A-F) . This implies that peripheral CD20 + T cells from healthy controls may have a similar potential for CNS migration as those from patients with RRMS.
CD20 + T cells in the CSF correlate with disease
Breakdown of myelin sheaths is a pathological hallmark of RRMS associated with immune cell activity (Popescu and Lucchinetti, 2012) . We therefore hypothesized that the CSF level of myelin basic protein (MBP), a structural component of myelin, correlated with the prevalence of CSF resident CD20 + T cells. Testing this hypothesis showed that the percentage of CD20 + T cells in the CSF of patients with multiple sclerosis positively correlated with the level of MBP (P = 0.0048; Fig. 3A) . Furthermore, we found a correlation between the percentage of CD20 + T cells in the CSF and disease severity assessed by the Expanded Disability Status Scale (EDSS), although this correlation was only suggestive (P = 0.0101; Fig. 4B ). No correlation was found between the percentage of CD20 + T cells in the CSF and the CSF white blood cell count (P = 0.335; r s = 0.256), the IgG index (P = 0.480; r s = 0.205), or the percentage of B cells in the CSF (P = 0.235; r s = 0.315).
Increased antigen reactivity of CD20 + T cells
Considering the high prevalence of CD20 + T cells in the CSF of patients with RRMS and its positive correlation with disease, CD20 + T cells are likely to be involved in T cell-mediated tissue damage in multiple sclerosis. Therefore, we challenged PBMC from patients with RRMS and healthy controls with the CNS antigen MOG and MBP in vitro. After 7 days of culture we observed that CD4 + CD20 + T cells from patients with RRMS reacted more vigorously in response to the CNS antigens compared to CD20
À T cells (P = 0.0002 for MOG; P = 0.0048 for MBP; Fig. 5A and B). Comparing CD20 + T cell reactivity of patients and healthy controls showed no significant difference ( Supplementary Fig. 2G and H); although a trend to an increased MBP reactivity was observed in CD20 + T cells from patients with RRMS (6.6% proliferating cells in 
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healthy controls versus 13.6% in patients with RRMS; P = 0.072).
To ensure that the strong proliferative response of CD20 + T cells observed was not due to an activation-induced upregulation of the CD20 molecule on CD20 À cells, we isolated CD20 + and CD20 À T cells by FACS and cultured the cells for 3 days with a polyclonal stimulus (anti-CD3 antibody) with or without co-stimulation (anti-CD28 antibody). This confirmed that CD20 + T cells had an increased proliferative capacity compared to CD20 À T cells (P = 0.011; Fig. 5C and D). It demonstrated that optimal activation of CD20 + T cells requires co-stimulation, supporting the observation that CD20 + T cells express CD28 to the same degree as CD20 À T cells (data not shown). Furthermore, we observed a higher frequency of in vitro cultured CD20 + T cells expressing the apoptotic marker annexin V compared to cultured CD20 À T cells, although only suggestive (Fig. 5E and F) . To assess whether this was primarily an activation-induced property or a CD20 + T cell characteristic we measured the expression of the apoptotic markers Fas and Fas-ligand (FasL) on CD20 + and CD20 À T cells from freshly isolated PBMC. Here we found that the frequency of both Fas+ and FasL+ CD20 + T cells was significantly higher compared to CD20 À T cells from patients with RRMS (P 5 0.0001 for Fas; P = 0.0002 and P = 0.0039 for FasL; Fig. 5G and H) and healthy control (P 5 0.0001 for Fas; P 5 0.0001 and P = 0.0018 for FasL). There was no significant difference between Fas and FasL expression on CD20 + T cells from patients and healthy controls ( Supplementary Fig. 2I and J).
CD20
+ T cells are found within all differential stages Next, we investigated if the strong reactivity of CD20 + T cells observed was due to the cells being previously Correlation between per cent CD20 + T cells in the CSF and EDSS.
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activated. For this, CD20 + and CD20 À T cells were stained with the early activation marker CD69 and the late activation marker HLA-DR. This showed that only a minor fraction of both CD20 + and CD20 À T cells expressed CD69 and HLA-DR ( Fig. 6A and B) , suggesting that CD20 + T cells do not represent a uniform population of previously antigen-primed T cells. Therefore, we examined the differential stages of CD20 + T cells. For this, expression of the T cell differentiation markers CCR7 and CD45RA was analysed on freshly isolated T cells, and showed that CD20 + T cells are found within all T cell stages in adults; i.e. naïve, central memory, effector memory and terminally differentiated (TEMRA) T cells. However, significantly fewer naïve T cells and more memory T cells were found in the CD20 + T cell population compared to the CD20 À T cell population in patients with RRMS ( Fig. 6D-I ) and in healthy controls (Supplementary Fig. 2K-P) . Comparing the distribution of CD20 + T cells within the differential stages from patients with RRMS and healthy controls showed a higher percentage of effector memory and late-effector memory CD20 + T cells (P 5 0.05) and a smaller percentage of naïve CD20 + T cells from patients with RRMS (P 5 0.001) (Supplementary Fig. 2K-P) ; although only suggestive.
To evaluate whether we are born with CD20 + T cells or if they develop later in life we drew cord blood from six newborn individuals. As expected, all cord blood T cells were naïve (Supplementary Fig. 3A ) and did not express the exhaustion marker CD57 (data not shown). However, CD20 + T cells were not detected in the cord blood, indicating that these cells develop later in life ( Supplementary  Fig. 3B and C).
CD20 + T cells are Th1/Tc1-like
To elucidate the functional properties of CD20 + T cells, we isolated CD20 + and CD20 À T cells by FACS, challenged them with PMA/ionomycin and measured their production of cytokines by flow cytometry. This showed that increased production of IFN (P 5 0.0001), TNF (P = 0.0008 for CD4 + ; P = 0.0006 for CD8 + ), IL-4 (P = 0.0006 for CD4 + ), GM-CSF (P = 0.011 for CD4 + ) and IL-13 (P = 0.014 for CD4 + ) were properties of CD20 + T cells; although only suggestive for GM-CSF and IL-13 (Fig. 7A-E and data not shown). IL-17 was also measured, and although produced by a fraction of CD4 + CD20 + T cells (0.9%), a higher percentage of CD4 + CD20 À T cells produced IL-17 (1.7%; P = 0.0365). To substantiate these findings, the sorted T cell populations were cultured for 0-7 days with a polyclonal stimulus (anti-CD3 antibody) with or without costimulation (anti-CD28 antibody) and culture supernatants analysed for the cytokines in question. This confirmed that CD20 + T cells produce higher levels of IFN, TNF and GM-CSF and with a much faster kinetic (Fig. 7F-H) . A parallel measurement of a variety of chemokines was included in the analysis, and demonstrated that particularly The mean value is shown for all groups analysed.
CCL3 (MIP-1) was substantially increased in the cell cultures of CD20 + T cells (Fig. 7I) . A survival analysis showed that after 5 days in culture with a polyclonal stimulus the CD20 + T cells underwent activation-induced cell death while CD20 À T cells were still fully viable (data not shown).
Production of IFN, TNF and GM-CSF coincides with a Th1 and Tc1 phenotype of CD4 + and CD8 + CD20 + T cells, respectively. To confirm this phenotype we examined the expression of the transcription factor Tbet in CD20 À and CD20 + T cells. In agreement with the suggested Th1/ Tc1 phenotype, we found a higher frequency of Tbet expressing CD20
+ T cells (P = 0.0005; P = 0.023; Fig. 7J ). We found no co-expression of Tbet and RORt in CD20 + T cells, although a subset of CD20 + T cells expressed RORt (data not shown).
Long term depletion of CD20 + T cells following treatment with alemtuzumab
To substantiate the involvement of CD20 + T cells in the pathogenesis of RRMS, we analysed the effect of treatment with the lymphocyte-depleting anti-CD52 antibody alemtuzumab on CD20 + T cells. Despite the partial recovery of the peripheral T cell pool after 2 years of treatment, we found that CD20 + T cells were barely replaced in the treated RRMS patients; mean 1.99% CD20 + T cells in treated compared to 7.73% in untreated patients (P 5 0.0001; Fig. 8A ). The prevalence of CD20 + T cells was also very low in the CSF of the alemtuzumab treated patients (P = 0.0016; Fig.  8B) ; and the treatment-induced reduction even greater than observed for CD20 + B cells (Fig. 8D) . Analysing the phenotype of the few CD20 + T cells found within the blood of treated RRMS patients showed an increased ratio between CD4 and CD8 T cells compared to untreated patients; although only suggestive (P = 0.029; Fig. 8C) . Furthermore, the distribution of naïve and memory CD20 + T cell populations were comparable to that of untreated patients; although a trend towards an increased naïve population was found in alemtuzumab treated patients (P = 0.029). Finally, we found that the frequency of CD20 + T cells expressing CD49d hi (P 5 0.0001), CCR2 (P 5 0.0001), and CXCR3 (P 5 0.0009 for CD8 + cells) was significantly decreased following treatment; whereas no change in CCR5, CCR6 or MCAM-1 was observed (Fig. 8E-G and data not shown).
Discussion
Recent studies have established the existence of a T cell subset expressing low levels of CD20; however, there have been discrepancies about the origin of these cells. Bremer and co-workers suggested that the CD20 molecule was transferred from B cells to T cells in a process termed trogocytosis (de Bruyn et al., 2015) . Various studies have documented MS4A1/CD20 mRNA in CD20 + T cells and furthermore CD20 + T cells have been found in the thymus where B cells are not present (Wilk et al., 2009; Schuh et al., 2016) ; trogocytosis therefore unlikely accounts for the majority of CD20 expressed on the surface of CD20 + T cells. In agreement with these observations we and others (Palanichamy et al., 2014) found that CD20 is expressed in both naïve and memory T cells and that only a small fraction of CD20 + T cells express activation markers; trogocytosis only takes place following T cell receptor triggering. From these observations we hypothesized that CD20 + T cells represent a distinct cell lineage. Krumbholz and coworkers observed CD20 + T cells in thymic samples from very young children (593 days old) (Schuh et al., 2016) strengthening the perception of CD20 + T cells being a cell lineage; and implying that CD20 + T cells develop very early in life. Analysing cord blood samples from newly born individuals, however, showed that we are not born with CD20 + T cells. In this study we investigated a potential role of CD20 + T cells in the pathogenesis of RRMS. RRMS pathogenesis includes activation of CNS-Ag specific T cells in the periphery and recruitment of these cells to the CNS where reactivation induces effector functions leading to nervous tissue damage (Dendrou et al., 2015) . Analysing the CNS migratory potential of peripheral CD20 + T cells from patients with RRMS showed that a higher frequency of blood CD20 + T cells expressed adhesion molecules (CD49d hi , MCAM-1) and chemokine receptors (CCR2, CCR5, CCR6, CXCR3) associated with migration of blood lymphocytes to the CNS (Barrau et al., 2000; Fife et al., 2000; Reboldi et al., 2009; Sporici and Issekutz, 2010; Schneider-Hohendorf et al., 2014; Kara et al., 2015; Larochelle et al., 2015; Gu et al., 2016; Saraste et al., 2016) than the corresponding CD20 À T cells. In coherence we observed enrichment of CD20 + T cells in the CSF of patients with RRMS particularly associated with an overall CCR2+ CCR5+ pattern and additionally a CCR6+ MCAM-1+ pattern for the CD4 population in contrast to CD20 À T cells. The vast majority of T cells found in the CSF expressed high levels of CD49d and CXCR3 regardless of their CD20 status, demonstrating that CD49d and CXCR3 likely are molecules used by all T cells to navigate to the CSF. Comparing the adhesion molecule and chemokine receptor phenotype of CD20 + T cells from patients with RRMS and healthy controls showed no difference between the two groups; indicating that peripheral CD20 + T cells from healthy controls possess the ability to migrate to the CNS equally well. Previous studies have documented a significantly higher level of CSF chemokines used to attract 
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T cells expressing the chemokine receptors associated with CD20 + T cells; e.g. CXCL10, which attracts CXCR3+ T cells and which may play a critical role in RRMS (Sorensen et al., 2002; Vazirinejad et al., 2014) . In addition, we documented an increased prevalence of CD20 + T cells in the blood of patients with RRMS compared to healthy controls, confirming an observation from a smaller study of Palanichamy et al. (2014) . This increased level of CD20 + T cells in the blood together with the earlier observation of high levels of migratory factors in the CSF of patients with RRMS likely accounts for the accumulation of CD20 + T cells observed in the CSF. A possible implication of CD20 + T cells in the pathogenesis of RRMS is strengthened by our finding of a positive correlation between CSF resident CD20 + T cells and myelin sheath breakdown (MBP) and the severity of disease (EDSS).
Strikingly, in patients with RRMS treated for 2 years with the highly effective leucocyte-depleting treatment alemtuzumab, we observed a depletion of CD20 + T cells despite a partial recovery of the T cell pool. Likewise, the prevalence of CD20 + T cells in the CSF of alemtuzumabtreated patients was extremely low. The few CD20
+ T cells present in the circulation of treated patients had significantly decreased expression of CD49d hi , CCR2 and CXCR3 likely compromising their ability to migrate to the CSF. These observations support the hypothesis that CD20 + T cells play a central role in multiple sclerosis pathogenesis and moreover, that depletion of these cells may contribute to the positive treatment effects of with alemtuzumab.
To elucidate the effector mechanism by which CD20 + T cells may contribute to the pathogenesis of RRMS, we analysed the cytokine production potential of CD20 + T cells. In contrast to CD20 À T cells a great proportion of CD4 + and the majority of CD8 + CD20 + T cells produced IFN, TNF and GM-CSF; all cytokines previously shown to be implicated in the pathogenesis of multiple sclerosis (Sospedra and Martin, 2005; Shiomi and Usui, 2015) . This cytokine profile corresponds to a Th1 and Tc1 phenotype, a proposal confirmed by the presence of the Th1 and Tc1-associated transcription factor Tbet (Knox et al., 2014) . Interestingly in a study by Kara et al. (2015) , a Tbet/IFN/TNF/GM-CSF expressing encephalitogenic Th17 cell type was shown to induce disease dependent on CCR2-directed CNS migration. This observation emphasizes the likelihood of a pathogenic role of the Tbet/IFN/ TNF/GM-CSF expressing CCR2+ CD20 + T cells described in our study. Although CD4 + T cells historically have attracted more attention in multiple sclerosis research than their CD8 counterparts, the decreased CD4:CD8 ratio in the CD20 + T cell population observed by us and those of others (Wilk et al., 2009; Palanichamy et al., 2014) together with the notion that CD8 + CD20 + T cells are more prominent producers of the pro-inflammatory cytokines IFN and TNF establishes a central role of CD8 + CD20 + T cells in inflammation. In addition to IFN, TNF and GM-CSF we also found that CD20 + T cells produced large amounts of the chemokine CCL3 (MIP-1) in marked contrast to CD20 À T cells. In Alzheimer's disease, peripheral T cells expressing high levels of CCL3 were shown to enhance the T cells crossing of the human blood-brain barrier (Man et al., 2007) and in multiple sclerosis CCL3 has been shown to increase the adhesion of T cells to human brain microvessel endothelial cells, which constitute the blood-brain barrier; a process further enhanced by IFN and TNF (Liu and DoroviniZis, 2012 ). In addition to T cell transmigration, CCL3 has also been shown to regulate dendritic cell recruitment to the CNS (Zozulya et al., 2007) . The high CCL3 production of CD20 + T cells described in our study therefore possibly enhances CNS inflammation through recruitment of immune cells from the blood.
Besides enrichment of IFN/TNF/GM-CSF producing CD20 + T cells in the CSF of patients with RRMS described in the current study, others have found enrichment of CD20 + T cells with a Th1/Tc1-signature in the synovial fluid from patients with rheumatoid arthritis (Wilk et al., 2009) and in peritoneal ascites fluid of patients with ovarian cancer (de Bruyn et al., 2015) ; strengthening the hypothesis of CD20 + T cells as active players in tissue inflammation. An earlier study also observed CD20 + T cells in the CSF of patients with multiple sclerosis; however, they could not confirm the enrichment found in our study (Schuh et al., 2016) . Their number of subjects included was considerably smaller and to our knowledge, handling of CSF samples is crucial for the survival of apoptosis-sensitive immune cells. Although verification by others is warranted, we found that the percentage of CD20 + T cells was higher in the CSF sample from all included patients compared to their blood samples.
Intriguingly, our data indicate that CD20 + T cells are highly reactive T cells; i.e. they have an increased level and a faster kinetic of both proliferation and pro-inflammatory cytokine production. Still, no evidence suggests that peripheral CD20 + T cells are exclusively antigen-primed T cells; i.e. only a small subset express activation markers and both naïve and memory CD20 + T cells are found in the blood. However, the differentiation state of CD20 + T cells is skewed towards a memory phenotype compared to CD20 À T cells, possibly reflecting that this cell population is involved in immune reactions in both healthy controls and patients. Furthermore, we found that the frequency of CD20 + effector memory T cells was increased and naïve T cells decreased in patients with RRMS compared to healthy controls; possibly reflecting an increased activation of the CD20 + T cell pool in the blood of patients. Which molecular mechanisms control the cell reactivity of CD20 + T cells is unknown. One could speculate that signalling through the CD20 molecule introduces epigenetic changes, which lowers the activation threshold of certain biological pathways; however, this area of research awaits further investigation.
Until now, the strong efficacy of anti-CD20 antibody therapy in reducing disease progression in patients with RRMS has been attributed to the depletion of B cells, and the reduced activity of T cells ascribed to the lack of stimuli from the depleted B cells. It is well accepted that B and T cells cooperate to optimize a strong T cell response (Christensen et al., 2003; Attanavanich and Kearney, 2004; Castiglioni et al., 2005) , and hence, the lack of B cells evidently will affect T cell activity. Nonetheless, studies now confirm the depletion of pro-inflammatory CD20 + T cells in treated patients (Wilk et al., 2009; Palanichamy et al., 2014; Schuh et al., 2016) , and a recent but small study suggests a correlation between relapses during rituximab treatment and the recovery of CD20 + T cells (Schuh et al., 2016) . In coherence we found that the number of CD20 + T cells in the CSF of patients with multiple sclerosis greatly outnumbers B cells (Fig. 8D) and a study by Holley et al. (2014) demonstrated that CD20 + T cells are present in the brain from patients with multiple sclerosis. Altogether, these observations substantiate that CD20 + T cells play a role in the pathogenesis of multiple sclerosis and that depletion of CD20 + T cells likely contributes to the positive treatment effect of anti-CD20 antibody therapies.
